Wire · founder news, decoded · regulatory
Sanofi Commitments Put Vaccine Disparagement Inside EU Antitrust Enforcement
The EU Commission is enforcing competition law against Sanofi for allegedly disparaging a rival influenza vaccine (Fluad) through misleading promotional claims, securing binding commitments including corrective statements on company websites and restrictions on negative messaging until March 2030.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
EU competition enforcement now extends to pharmaceutical disparagement and misleading health communications; founders in healthtech/pharma must audit promotional claims and align with expert assessments or face Article 102 abuse investigations and binding commitments.
Read the full story at eutoday.net →
Topics: Digital Health · antitrust-enforcement · pharmaceutical-marketing · eu-competition-law · article-102-abuse · health-authority-influence · regulatory-precedent